{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T11:18:49Z","timestamp":1789125529206,"version":"build-2803163510"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>\n                    A 66-year-old man with inoperable malignant scalp melanoma, refractory to immunotherapy, underwent\n                    <jats:sup>99m<\/jats:sup>\n                    Tc-HYNIC-TOC SPECT\/CT for evaluating the possibility of radioligand therapy with\n                    <jats:sup>177<\/jats:sup>\n                    Lu-DOTATATE, which demonstrated no tracer uptake in scalp lesions, precluding\n                    <jats:sup>177<\/jats:sup>\n                    Lu-DOTATATE therapy. Subsequent disease progression prompted\n                    <jats:sup>99m<\/jats:sup>\n                    Tc-FAPI-46 SPECT\/CT, which showed intense tracer uptake in lesions and prompted radioligand therapy with\n                    <jats:sup>177<\/jats:sup>\n                    Lu-FAPI-2286. After 4 cycles of treatment, all lesions showed regression and he was referred for tumor resection. This case illustrates the clinical utility of FAPI-based theranostic and shows\n                    <jats:sup>99m<\/jats:sup>\n                    Tc-FAPI SPECT\/CT can directly inform targeted radioligand therapy using\n                    <jats:sup>177<\/jats:sup>\n                    Lu-FAPI, thereby expanding therapeutic options in melanoma management.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000006681","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T11:00:43Z","timestamp":1789124443000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["177Lu-FAPI-2286 Radioligand Therapy in Refractory Scalp Melanoma"],"prefix":"10.1097","author":[{"given":"Haniye","family":"Elahifard","sequence":"first","affiliation":[{"name":"Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Hadi","family":"Samadi","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Bari","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ghaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Soltani","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Imam Reza University Hospital, Mashhad University of Medical Sciences, Mashhad"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Kamali","sequence":"additional","affiliation":[{"name":"Head of the Radiopharmaceuticals Diagnostic and Theranostic Kits Products Department, Pars Isotope Co, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atena","family":"Aghaee","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"R1-20260911","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s002680020102","article-title":"Distribution and functional significance of somatostatin receptors in malignant melanoma","volume":"25","author":"Lum","year":"2001","journal-title":"World J Surg"},{"key":"R2-20260911","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.3390\/diagnostics15182305","article-title":"Radiopharmaceuticals in malignant melanoma: a comprehensive review of diagnostic, therapeutic, and immune-related applications by PET\/CT, SPECT\/CT, and PET\/MRI","volume":"15","author":"Pirsan","year":"2025","journal-title":"Diagnostics"},{"key":"R3-20260911","first-page":"1097","article-title":"Comparative utility of 68Ga-FAPI PET\/CT and 18F-FDG PET\/CT in assessing treatment response in a case of metastatic anal melanoma with brain involvement","volume":"10","author":"Divband","year":"2022","journal-title":"Clin Nucl Med"},{"key":"R4-20260911","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1007\/s00259-022-05702-2","article-title":"[68 Ga] Ga-FAPI versus [18F] F-FDG in malignant melanoma: complementary or counterpoint?","volume":"49","author":"Mokoala","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R5-20260911","doi-asserted-by":"crossref","first-page":"12383","DOI":"10.3390\/ijms241512383","article-title":"Efficacy of pembrolizumab in advanced melanoma: a narrative review","volume":"24","author":"Rizzetto","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R6-20260911","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-025-01659-1","article-title":"Novel clinical PET tracers in the pipeline for melanoma","volume":"27","author":"Jaber","year":"2025","journal-title":"Curr Oncol Rep"},{"key":"R7-20260911","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4103\/ijnm.ijnm_79_24","article-title":"Fibroblast activation protein (FAP): a crucial modulator of the microenvironment in metastatic melanoma case","volume":"40","author":"Divband","year":"2025","journal-title":"Indian J Nucl Med"},{"key":"R8-20260911","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1177\/147323000903700617","article-title":"Expression of somatostatin receptors in human melanoma cell lines: effect of two different somatostatin analogues, octreotide and SOM230, on cell proliferation","volume":"37","author":"Martinez-Alonso","year":"2009","journal-title":"J Int Med Res"},{"key":"R9-20260911","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/CMR.0b013e32835b70e9","article-title":"Somatostatin receptor scintigraphy in patients with metastatic uveal melanoma","volume":"23","author":"Valsecchi","year":"2013","journal-title":"Melanoma Res"},{"key":"R10-20260911","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00259-023-06444-5","article-title":"Controversies of [68Ga] Ga-FAPI-46 and 2-[18F] FDG findings in metastatic melanoma","volume":"51","author":"Novruzov","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R11-20260911","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1097\/RLU.0000000000003854","article-title":"18F-FDG PET\/CT and 68Ga-FAPI-4 PET\/CT findings of bilateral knee osteoarthritis in a patient with uveal malignant melanoma","volume":"47","author":"Fenercio\u011flu","year":"2022","journal-title":"Clin Nucl Med"},{"key":"R12-20260911","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/RLU.0000000000004658","article-title":"Malignant melanoma of the external auditory canal on 68Ga-FAPI PET\/CT","volume":"48","author":"Liu","year":"2023","journal-title":"Clin Nucl Med"},{"key":"R13-20260911","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/RLU.0000000000003882","article-title":"Increased 68Ga-FAPI activity in malignant melanoma of the nasal cavity","volume":"47","author":"Ou","year":"2022","journal-title":"Clin Nucl Med"},{"key":"R14-20260911","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4103\/ijnm.ijnm_123_24","article-title":"Unexpectedly low FDG and FAPI uptake in mucosal melanoma: case report with literature review","volume":"40","author":"Ajit","year":"2025","journal-title":"Indian J Nucl Med"},{"key":"R15-20260911","first-page":"1097","article-title":"18F-FDG versus 68Ga-FAPI PET\/MRI findings in a case of primary gastric melanoma","volume":"10","author":"Yang","year":"2022","journal-title":"Clin Nucl Med"},{"key":"R16-20260911","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.7150\/thno.106108","article-title":"Therapeutic potential of FAPI RLT in oncology: a systematic review","volume":"15","author":"Ruzzeh","year":"2025","journal-title":"Theranostics"},{"key":"R17-20260911","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.3390\/cancers14194575","article-title":"Evaluating the combined anticancer response of checkpoint inhibitor immunotherapy and FAP-targeted molecular radiotherapy in murine models of melanoma and lung cancer","volume":"14","author":"Capaccione","year":"2022","journal-title":"Cancers"},{"key":"R18-20260911","first-page":"1097","article-title":"FAP-targeted theranostics in advanced sarcoma: a pilot study of \u2076\u2078Ga-FAPI-46 imaging and \u00b9\u2077\u2077Lu-FAPI-2286 therapy","volume":"10","author":"Jokar","year":"2022","journal-title":"Clin Nucl Med"},{"key":"R19-20260911","doi-asserted-by":"crossref","first-page":"e602","DOI":"10.1097\/RLU.0000000000005794","article-title":"Enhancing initial staging of a gastric cancer patient: the advantage of [99mTc]-FAPI-46 SPECT\/CT over conventional CT","volume":"50","author":"Elahifard","year":"2025","journal-title":"Clin Nucl Med"},{"key":"R20-20260911","doi-asserted-by":"crossref","first-page":"e686","DOI":"10.1097\/RLU.0000000000005862","article-title":"Diffuse FAPI-46 uptake in bone marrow: a case of primary myelofibrosis with superscan pattern on bone scintigraphy","volume":"50","author":"Elahifard","year":"2025","journal-title":"Clin Nucl Med"},{"key":"R21-20260911","doi-asserted-by":"crossref","first-page":"e811","DOI":"10.1097\/RLU.0000000000006505","article-title":"Theranostic Application of FAPI in Advanced Laryngeal Squamous Cell Carcinoma: 99m Tc-FAPI-46 SPECT\/CT Guided 177 Lu-FAPI-2286 Therapy.","volume":"51","author":"Elahifard","year":"2026","journal-title":"Clin Nucl Med"},{"key":"R23-20260911","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.1097\/RLU.0000000000005746","article-title":"Remarkable 99mTc-FAPI-46 Uptake in a Patient With Anaplastic Thyroid Carcinoma: A Promising Step in Theranostic Field.","volume":"50","author":"Ghahraman","year":"2025","journal-title":"Clin Nucl Med"},{"key":"R22-20260911","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1186\/s12885-026-16270-1","article-title":"[\u00b9\u2077\u2077Lu]Lu-FAPI-2286 radioligand therapy in heavily pre-treated patients with advanced breast and gastrointestinal cancers: a single-center retrospective experience.","volume":"26","author":"Rabani","year":"2026","journal-title":"BMC Cancer"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006681","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T11:00:46Z","timestamp":1789124446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":23,"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006681","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"2026-05-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}